MCID: GST049
MIFTS: 59

Gastrointestinal System Cancer

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastrointestinal System Cancer

MalaCards integrated aliases for Gastrointestinal System Cancer:

Name: Gastrointestinal System Cancer 12 15
Digestive System Neoplasms 44 73
Gastrointestinal Neoplasms 44 73
Malignant Neoplasm of Gastrointestinal Tract 73
Neoplasm of the Gastrointestinal Tract 29
Gastrointestinal Tract Cancer 12
Cancer of Digestive System 73
Digestive System Cancer 12
Gi Tumor 12

Classifications:



Summaries for Gastrointestinal System Cancer

Disease Ontology : 12 An organ system cancer located in gastrointestinal tract that is manifested in organs of the gastrointestinal system.

MalaCards based summary : Gastrointestinal System Cancer, also known as digestive system neoplasms, is related to oral cavity cancer and pharynx cancer, and has symptoms including signs and symptoms, digestive An important gene associated with Gastrointestinal System Cancer is HOTAIR (HOX Transcript Antisense RNA
The results found a significant association between expression of HOX transcript antisense intergenic RNA and poor overall survival in digestive cancers (pooled hazard ratio = 2.19, 95% confidence interval, 1.86-2.57, P < .001). Furthermore, subgroup analysis showed that tumor type, region, Newcastle-Ottawa scale, and sample size did not alter the predictive value of HOX transcript antisense intergenic RNA as an independent factor for patients' survival. In addition, we also revealed that the clinicopathological characteristics such as differentiation, lymph node metastasis, tumor node metastasis (TNM) stage, and distant metastasis were positively related to expression of HOX transcript antisense intergenic RNA digestive cancers.
Dysfunction Pattern: Regulation), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs GastroMARK and Gleevec have been mentioned in the context of this disorder. Affiliated tissues include gastrointestinal tract, lung and liver, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Gastrointestinal System Cancer

Diseases in the Gastrointestinal System Cancer family:

Gastrointestinal System Benign Neoplasm

Diseases related to Gastrointestinal System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 197)
# Related Disease Score Top Affiliating Genes
1 oral cavity cancer 33.1 CDH1 EGFR TP53 VEGFA
2 pharynx cancer 32.9 AKT1 CCND1 CDH1 EGFR TP53 VEGFA
3 gastrointestinal stromal tumor 32.8 AKT1 CCND1 EGFR HOTAIR KIT KRAS
4 gastric cancer 32.5 BANCR CCND1 CDH1 CTNNB1 EGFR H19
5 esophageal cancer 32.2 AKT1 CCND1 CDH1 CTNNB1 EGFR H19
6 pancreatic cancer 30.6 AKT1 CCND1 CDH1 CTNNB1 EGFR H19
7 neonatal inflammatory skin and bowel disease 11.4 ADAM17 EGFR
8 rare adenocarcinoma of the breast 11.3 AKT1 KRAS TP53
9 mature teratoma 11.3 AFP KRAS TP53
10 thymoma, familial 11.3 HRAS KIT
11 nasal cavity adenocarcinoma 11.3 HRAS KRAS TP53
12 paronychia 11.3 EGFR HRAS KRAS
13 biliary papillomatosis 11.3 HRAS KRAS TP53
14 aggressive digital papillary adenocarcinoma 11.3 HRAS KIT KRAS
15 pituitary adenoma 11.3 H19 HOTAIR MALAT1
16 ovarian epithelial cancer 11.3 H19 HOTAIR MALAT1
17 pulmonary blastoma 11.3 EGFR KRAS TP53
18 ovary adenocarcinoma 11.3 HRAS KRAS TP53
19 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 11.3 CTNNB1 KRAS TP53
20 sigmoid neoplasm 11.3 HRAS KRAS
21 anal squamous cell carcinoma 11.3 AKT1 MLH1 TP53
22 biliary tract neoplasm 11.3 HRAS KRAS TP53
23 acneiform dermatitis 11.3 EGFR HRAS KRAS
24 mucoepidermoid esophageal carcinoma 11.3 TP53 WWOX
25 liver angiosarcoma 11.3 HRAS KRAS TP53
26 ethmoid sinus cancer 11.3 CCND1 EGFR HRAS
27 triple-receptor negative breast cancer 11.3 HOTAIR MALAT1
28 ethmoid sinus adenocarcinoma 11.3 CCND1 EGFR HRAS
29 adenosquamous cell lung carcinoma 11.3 EGFR HRAS KRAS
30 pleomorphic carcinoma 11.3 EGFR KIT TP53
31 embryonal sarcoma 11.3 CTNNB1 KIT MALAT1 TP53
32 acinar cell carcinoma 11.3 AFP CTNNB1 TP53
33 esophagus sarcoma 11.3 KIT WWOX
34 thyroid cancer, nonmedullary, 1 11.3 BANCR H19 HOTAIR MALAT1
35 core binding factor acute myeloid leukemia 11.3 HRAS KIT KRAS
36 mixed cell type cancer 11.3 HRAS KIT KRAS TP53
37 exanthem 11.3 EGFR HRAS KRAS TLR9
38 osteogenic sarcoma 11.3 BANCR H19 HOTAIR MALAT1 TP53
39 soft tissue sarcoma 11.3 EGFR TP53 VEGFA
40 brain ependymoma 11.3 EGFR TP53
41 hepatoblastoma 11.3 AFP CTNNB1 H19 TP53
42 esophageal basaloid squamous cell carcinoma 11.3 CTNNB1 EGFR TP53 WWOX
43 melanocytic nevus syndrome, congenital 11.3 HRAS MLH1 MSH2
44 lung benign neoplasm 11.3 EGFR HRAS KRAS TP53
45 atypical teratoid rhabdoid tumor 11.3 CCND1 CTNNB1 HOTAIR TP53
46 skin squamous cell carcinoma 11.3 HRAS KRAS TP53
47 signet ring cell adenocarcinoma 11.3 CDH1 CTNNB1 TP53
48 lung adenoid cystic carcinoma 11.3 EGFR HRAS KIT KRAS
49 hidradenocarcinoma 11.3 CCND1 EGFR TP53
50 tubular adenocarcinoma 11.3 AFP CDH1 EGFR

Comorbidity relations with Gastrointestinal System Cancer via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Cholestasis Deficiency Anemia
Heart Disease Intestinal Obstruction
Iron Deficiency Anemia Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Gastrointestinal System Cancer:



Diseases related to Gastrointestinal System Cancer

Symptoms & Phenotypes for Gastrointestinal System Cancer

UMLS symptoms related to Gastrointestinal System Cancer:


signs and symptoms, digestive

GenomeRNAi Phenotypes related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.48 KRAS HRAS EGFR
2 Decreased viability GR00106-A-0 10.48 KRAS
3 Decreased viability GR00221-A-1 10.48 EGFR HRAS AKT1 KIT CDH1 KRAS
4 Decreased viability GR00221-A-2 10.48 HRAS AKT1 KRAS
5 Decreased viability GR00221-A-3 10.48 HRAS AKT1
6 Decreased viability GR00221-A-4 10.48 EGFR AKT1
7 Decreased viability GR00301-A 10.48 KRAS KIT CDH1 MSH2
8 Decreased viability GR00381-A-1 10.48 KRAS
9 Decreased viability GR00402-S-2 10.48 EGFR KRAS HRAS AKT1 KIT CDH1
10 Decreased cell migration GR00055-A-1 9.73 HRAS ADAM17 AKT1 KRAS CTNNB1 EGFR
11 Increased cell migration GR00055-A-3 9.35 EGFR ADAM17 HRAS CTNNB1 KRAS
12 Reduced mammosphere formation GR00396-S 9.28 H19 HRAS ADAM17 AFP CCND1 CDH1

MGI Mouse Phenotypes related to Gastrointestinal System Cancer:

46 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.47 KIT HRAS TP53 MLH1 KRAS MSH2
2 cellular MP:0005384 10.46 KIT MLH1 KRAS MSH2 TLR9 VEGFA
3 endocrine/exocrine gland MP:0005379 10.44 KIT HRAS MLH1 KRAS TP53 WWOX
4 digestive/alimentary MP:0005381 10.42 KRAS KIT HRAS MSH2 TLR9 TP53
5 mortality/aging MP:0010768 10.41 KIT HRAS MLH1 KRAS MSH2 TLR9
6 immune system MP:0005387 10.37 KIT KRAS MSH2 TLR9 VEGFA TP53
7 cardiovascular system MP:0005385 10.36 HRAS EGFR KIT KRAS VEGFA TP53
8 growth/size/body region MP:0005378 10.36 KIT HRAS EGFR KRAS WWOX VEGFA
9 integument MP:0010771 10.36 KIT HRAS MLH1 KRAS MSH2 TP53
10 hematopoietic system MP:0005397 10.35 EGFR KIT MSH2 KRAS TLR9 VEGFA
11 neoplasm MP:0002006 10.32 KRAS KIT HRAS MSH2 TP53 MLH1
12 embryo MP:0005380 10.25 EGFR KIT KRAS VEGFA TP53 AKT1
13 nervous system MP:0003631 10.23 HRAS EGFR KIT MSH2 KRAS VEGFA
14 craniofacial MP:0005382 10.21 HRAS EGFR KIT KRAS VEGFA TP53
15 liver/biliary system MP:0005370 10.18 EGFR KIT KRAS VEGFA TP53 WWOX
16 normal MP:0002873 10.14 KIT HRAS KRAS VEGFA TP53 CCND1
17 muscle MP:0005369 10.1 EGFR KIT KRAS VEGFA TP53 AKT1
18 no phenotypic analysis MP:0003012 10.09 EGFR KIT HRAS KRAS VEGFA TP53
19 limbs/digits/tail MP:0005371 10.08 EGFR KIT KRAS VEGFA TP53 ADAM17
20 reproductive system MP:0005389 10.07 KIT TP53 MLH1 KRAS WWOX VEGFA
21 renal/urinary system MP:0005367 9.92 HRAS EGFR KIT KRAS TLR9 VEGFA
22 respiratory system MP:0005388 9.9 KIT HRAS TP53 MLH1 KRAS VEGFA
23 pigmentation MP:0001186 9.85 EGFR KIT KRAS TP53 ADAM17 CTNNB1
24 skeleton MP:0005390 9.7 EGFR KIT HRAS KRAS VEGFA TP53
25 vision/eye MP:0005391 9.28 EGFR KIT MLH1 KRAS VEGFA TP53

Drugs & Therapeutics for Gastrointestinal System Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
GastroMARK 18 FERUMOXSIL Advanced Magnetics May 1996
2
Gleevec 18 49 IMATINIB MESYLATE Novartis May 2001
3
SecreFlo 18 SECRETIN SECRETIN SYNTHETIC PORCINE Repligen April 2002
4
Stivarga 18 49 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
5
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006

Drugs for Gastrointestinal System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 308)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 5310940 9887054 43805 6857599
2
Celecoxib Approved, Investigational Phase 4,Phase 1 169590-42-5 2662
3 Parecoxib Approved Phase 4 198470-84-7
4
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
5
Fluorouracil Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-21-8 3385
6
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
7
Insulin Glargine Approved Phase 4 160337-95-1
8
Zinc Approved, Investigational Phase 4 7440-66-6 23994
9
Enoxaparin Approved Phase 4 9005-49-6 772
10
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
11
Clarithromycin Approved Phase 4 81103-11-9 84029
12
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
13 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
15 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1,Phase 2
16 Analgesics, Opioid Phase 4
17 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Not Applicable
18 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 1
19 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
20 Central Nervous System Depressants Phase 4,Phase 3
21 Cyclooxygenase 2 Inhibitors Phase 4,Phase 3,Phase 1
22 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 1
23 insulin Phase 4
24 Insulin, Globin Zinc Phase 4
25 Narcotics Phase 4
26 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
27 Vitamins Phase 4,Phase 2,Phase 1,Not Applicable
28 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2,Not Applicable
29 Anticoagulants Phase 4,Phase 1,Not Applicable
30 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Neuromuscular Agents Phase 4
35 Neuromuscular Blocking Agents Phase 4
36 Neuromuscular Nondepolarizing Agents Phase 4
37 Hypoglycemic Agents Phase 4,Phase 1,Phase 2,Not Applicable
38 Antacids Phase 4
39 Anti-Ulcer Agents Phase 4
40 Proton Pump Inhibitors Phase 4
41 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1
42 Vasodilator Agents Phase 4,Phase 1,Early Phase 1
43 Fibrinolytic Agents Phase 4,Not Applicable
44 Cytochrome P-450 CYP3A Inhibitors Phase 4
45 Cytochrome P-450 Enzyme Inhibitors Phase 4
46 HIV Protease Inhibitors Phase 4,Phase 1,Phase 2,Not Applicable
47
protease inhibitors Phase 4,Phase 1,Phase 2,Not Applicable
48 Bufanolides Phase 4
49 Antihypertensive Agents Phase 4,Early Phase 1
50 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 383)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
3 Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery Unknown status NCT00790140 Phase 4
4 Nutritional Supplementation in Patients With no Signs of Malnutrition Unknown status NCT01894828 Phase 4
5 Medium Calorie Parenteral Nutrition on Patients With Gastrointestinal Cancer Undergoing Surgery Completed NCT01700062 Phase 4
6 The Laparotomy Study Completed NCT02140593 Phase 4 Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).;Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.
7 Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN) Completed NCT02216799 Phase 4 Glargine Insulin;Regular insulin
8 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4 Reconvan;Peptisorb
9 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
10 Comparison of Thromboembolic Events Between Enoxa® and Lovenox® in Patients Undergoing Digestive Cancer Recruiting NCT02444572 Phase 4 Enoxaparin 4000 UI
11 10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication Recruiting NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
12 Clinical Trial of Cinobufacini Injection Combined With Oxaliplatin Regimen on Gastrointestine Carcinoma Not yet recruiting NCT02860429 Phase 4 Cinobufacini injection;chemotherapy
13 Aliskiren Study of Safety and Efficacy in Senior Hypertensives Withdrawn NCT01922141 Phase 4 Aliskiren;Amlodipine;Ramipril;Hydrochlorothiazide
14 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
15 Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer Unknown status NCT00209742 Phase 3 UFT;USEL/Leucovorin;Krestin
16 Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial Unknown status NCT00164892 Phase 3 Oral Vioxx (Rofecoxib)
17 Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial Unknown status NCT00165048 Phase 3 Vioxx (Rofecoxib)
18 Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers Unknown status NCT02161991 Phase 3 Aprepitant;placebo
19 Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer Completed NCT02486198 Phase 3 placebo;GM;oxaliplatin-based chemotherapy
20 Home Enteral Nutrition in Malnourished Patients With Gastrointestinal Cancer Completed NCT02664974 Phase 3
21 Immunonutrition and Quality of Life of Cancer Patients Undergoing Oncological Treatment Completed NCT01423799 Phase 3
22 Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting Completed NCT00971399 Phase 3 ramosetron;ondansetron
23 Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery Completed NCT00798447 Phase 3 MLF 541;Lipofundin MCT
24 Efficacy of an Oral Formula in Prevention of Anti-cancer Therapy Side Effects Completed NCT00455247 Phase 3 Glutamine
25 Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients Completed NCT00513357 Phase 3 Melatonin;Placebo
26 Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet Completed NCT01775449 Phase 3
27 Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma Completed NCT01829178 Phase 2, Phase 3 Silymarin;Placebo;chemotherapy
28 Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis Completed NCT00052962 Phase 3
29 Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer Completed NCT01360853 Phase 3 ON 01910.Na;Gemcitabine;Gemcitabine
30 Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients Completed NCT01523431 Phase 2, Phase 3 Irinotecan Injection [Camptosar];5-fluorouracil;Leucovorin
31 Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Recruiting NCT02853474 Phase 3
32 Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer Recruiting NCT02956876 Phase 3 standard chemotherapy for colorectal cancer
33 Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Recruiting NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
34 SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients Recruiting NCT03448549 Phase 3 Oxaliplatin;Tegafur,gimeracil and oteracil potassium;Xeloda
35 Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1) Recruiting NCT03199989 Phase 3 CapeOX(Capecitabine+Oxaliplatin)
36 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Active, not recruiting NCT02349412 Phase 3
37 Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index Not yet recruiting NCT02576080 Phase 3 Imatinib
38 Study of Romiplostim for Chemo-induced Thrombocytopenia in Adults Subjects With Gastrointestinal or Colorectal Cancer Not yet recruiting NCT03362177 Phase 3
39 IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer Suspended NCT00316745 Phase 3 Campto, Topotesin;TS-1;L-Plat;Isovorin;5-FU
40 Effects of 3 Day Preoperative Immunonutrition in Well-nourished Patients With Gastrointestinal (GI) Cancer Undergoing Surgery Terminated NCT01023412 Phase 3
41 Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
42 A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients Terminated NCT00254436 Phase 3 Procrit (epoetin alfa)
43 Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients Terminated NCT00516269 Phase 3 Methylphenidate;Placebo
44 Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo Terminated NCT00332280 Phase 2, Phase 3 AMT2003
45 Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer Unknown status NCT00209651 Phase 2 Campto, Topotesin;TS-1
46 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Unknown status NCT00019474 Phase 2 fluorouracil;hydroxyurea
47 Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis Unknown status NCT00454519 Phase 2
48 Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) in Patients With Advanced Gastric Cancer Unknown status NCT01980407 Phase 2 S-1, leucovorin, oxaliplatin
49 Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer Unknown status NCT00453323 Phase 2 Paclitaxel;Capecitabine
50 Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Tumors Unknown status NCT00691691 Phase 2

Search NIH Clinical Center for Gastrointestinal System Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: digestive system neoplasms

Genetic Tests for Gastrointestinal System Cancer

Genetic tests related to Gastrointestinal System Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Gastrointestinal Tract 29

Anatomical Context for Gastrointestinal System Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Gastrointestinal System Cancer:

19
Gastrointestinal Tract

MalaCards organs/tissues related to Gastrointestinal System Cancer:

41
Lung, Liver, Testes, Bone, Pancreas, Endothelial, Colon

Publications for Gastrointestinal System Cancer

Articles related to Gastrointestinal System Cancer:

# Title Authors Year
1
The effect of chemotherapy on nutritional status and weakness in geriatric gastrointestinal system cancer patients. ( 29429533 )
2018
2
The effect of intraoperative hypothermia upon blood transfusion needs and length of stay among gastrointestinal system cancer surgery. ( 28417506 )
2017
3
Perioperative immunonutrition ameliorates the postoperative immune depression in patients with gastrointestinal system cancer (prospective clinical study in 42 patients). ( 15587331 )
2004

Variations for Gastrointestinal System Cancer

Expression for Gastrointestinal System Cancer

Search GEO for disease gene expression data for Gastrointestinal System Cancer.

Pathways for Gastrointestinal System Cancer

Pathways related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 127)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.29 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
2
Show member pathways
14.14 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
3
Show member pathways
13.96 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
4
Show member pathways
13.51 AKT1 CCND1 EGFR HRAS KIT KRAS
5
Show member pathways
13.46 ADAM17 AKT1 CCND1 EGFR HRAS KIT
6
Show member pathways
13.4 AKT1 CDH1 CTNNB1 EGFR HRAS KIT
7
Show member pathways
13.38 AKT1 CDH1 CTNNB1 EGFR HRAS KIT
8
Show member pathways
13.16 AKT1 EGFR HRAS KIT KRAS TP53
9
Show member pathways
13.13 AKT1 CTNNB1 EGFR HRAS KRAS VEGFA
10
Show member pathways
13.12 AKT1 CDH1 CTNNB1 HRAS KRAS TP53
11
Show member pathways
13.12 AKT1 CCND1 CTNNB1 EGFR HRAS KIT
12
Show member pathways
13.03 AKT1 EGFR HRAS KIT KRAS TP53
13
Show member pathways
13.03 AKT1 CCND1 CTNNB1 EGFR HRAS KIT
14
Show member pathways
13.02 AKT1 HRAS KRAS MLH1 MSH2 TP53
15
Show member pathways
13.01 ADAM17 AKT1 EGFR HRAS KRAS VEGFA
16
Show member pathways
13 AKT1 CCND1 CTNNB1 EGFR HRAS KRAS
17
Show member pathways
12.98 AKT1 CTNNB1 HRAS KRAS TP53
18
Show member pathways
12.9 ADAM17 AKT1 CCND1 EGFR HRAS KRAS
19 12.86 AKT1 EGFR HRAS KIT KRAS TP53
20
Show member pathways
12.84 AKT1 CCND1 CDH1 EGFR HRAS KRAS
21
Show member pathways
12.83 AKT1 EGFR HRAS KIT KRAS TP53
22
Show member pathways
12.82 AKT1 CCND1 EGFR HRAS KRAS
23
Show member pathways
12.81 AKT1 CDH1 CTNNB1 HRAS KRAS TP53
24
Show member pathways
12.78 AKT1 CDH1 CTNNB1 EGFR HRAS KIT
25
Show member pathways
12.77 AKT1 EGFR HRAS KRAS TP53
26
Show member pathways
12.75 AKT1 CCND1 CTNNB1 EGFR HRAS KRAS
27
Show member pathways
12.74 ADAM17 AKT1 CCND1 CTNNB1 HRAS
28
Show member pathways
12.73 AKT1 CCND1 CDH1 CTNNB1 EGFR HRAS
29
Show member pathways
12.68 AKT1 CCND1 CDH1 CTNNB1 EGFR HRAS
30
Show member pathways
12.66 AKT1 CTNNB1 EGFR HRAS KRAS MSH2
31
Show member pathways
12.64 AKT1 CCND1 CTNNB1 HRAS KRAS TP53
32 12.63 CCND1 EGFR HRAS KRAS TP53 VEGFA
33 12.62 CCND1 MLH1 MSH2 TP53 WWOX
34
Show member pathways
12.6 AKT1 EGFR HRAS KRAS TP53
35
Show member pathways
12.58 AKT1 CCND1 CDH1 CTNNB1 EGFR HRAS
36
Show member pathways
12.55 AKT1 CCND1 EGFR HRAS KRAS TP53
37
Show member pathways
12.54 CCND1 CTNNB1 EGFR HRAS KRAS
38
Show member pathways
12.54 AKT1 EGFR HRAS KRAS TLR9 VEGFA
39
Show member pathways
12.54 AKT1 CTNNB1 EGFR HRAS KRAS TP53
40
Show member pathways
12.52 AKT1 EGFR HRAS KIT KRAS
41 12.52 AKT1 CCND1 CTNNB1 HRAS KRAS TP53
42
Show member pathways
12.51 AKT1 CTNNB1 HRAS KRAS VEGFA
43 12.45 AKT1 CCND1 CDH1 CTNNB1 EGFR HRAS
44
Show member pathways
12.42 AKT1 CCND1 CTNNB1 HRAS
45
Show member pathways
12.42 AKT1 CCND1 EGFR HRAS
46
Show member pathways
12.41 AKT1 EGFR HRAS KRAS
47 12.39 CCND1 HRAS KRAS TP53
48
Show member pathways
12.35 AKT1 EGFR HRAS KRAS VEGFA
49
Show member pathways
12.34 AKT1 HRAS KRAS TP53 VEGFA
50
Show member pathways
12.31 AKT1 HRAS KRAS TLR9

GO Terms for Gastrointestinal System Cancer

Cellular components related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 8.96 CDH1 CTNNB1
2 cell-cell junction GO:0005911 8.92 ADAM17 AKT1 CTNNB1 KIT

Biological processes related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.98 AKT1 CTNNB1 EGFR HRAS TP53
2 cytokine-mediated signaling pathway GO:0019221 9.93 AKT1 CCND1 KIT KRAS TP53 VEGFA
3 negative regulation of gene expression GO:0010629 9.92 AKT1 CTNNB1 HRAS VEGFA
4 positive regulation of cell migration GO:0030335 9.88 ADAM17 EGFR HRAS KIT VEGFA
5 liver development GO:0001889 9.83 CCND1 EGFR KRAS
6 positive regulation of MAPK cascade GO:0043410 9.83 CTNNB1 EGFR HRAS KIT TLR9
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.82 AKT1 EGFR VEGFA
8 positive regulation of cell growth GO:0030307 9.82 ADAM17 AKT1 EGFR
9 Ras protein signal transduction GO:0007265 9.81 HRAS KRAS TP53
10 positive regulation of epithelial cell proliferation GO:0050679 9.78 EGFR HRAS VEGFA
11 cellular response to growth factor stimulus GO:0071363 9.77 AKT1 CTNNB1 EGFR
12 positive regulation of gene expression GO:0010628 9.76 AKT1 CTNNB1 HRAS KIT KRAS TLR9
13 positive regulation of blood vessel endothelial cell migration GO:0043536 9.75 ADAM17 AKT1 VEGFA
14 positive regulation of MAP kinase activity GO:0043406 9.72 EGFR HRAS KIT KRAS VEGFA
15 ERBB2 signaling pathway GO:0038128 9.71 EGFR HRAS KRAS
16 response to X-ray GO:0010165 9.67 CCND1 MSH2 TP53
17 tongue development GO:0043586 9.65 EGFR KIT
18 entry of bacterium into host cell GO:0035635 9.65 CDH1 CTNNB1
19 epidermal growth factor receptor signaling pathway GO:0007173 9.65 ADAM17 AKT1 EGFR HRAS KRAS
20 mitotic G1 DNA damage checkpoint GO:0031571 9.63 CCND1 TP53
21 positive regulation of cellular component movement GO:0051272 9.63 ADAM17 VEGFA
22 positive regulation of isotype switching to IgG isotypes GO:0048304 9.61 MLH1 MSH2
23 positive regulation of cell proliferation GO:0008284 9.61 ADAM17 AKT1 CCND1 CTNNB1 EGFR HRAS
24 response to isolation stress GO:0035900 9.6 HRAS KRAS
25 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.58 ADAM17 AKT1 EGFR
26 cellular response to indole-3-methanol GO:0071681 9.57 CDH1 CTNNB1
27 positive regulation of isotype switching to IgA isotypes GO:0048298 9.56 MLH1 MSH2
28 somatic recombination of immunoglobulin gene segments GO:0016447 9.55 MLH1 MSH2
29 response to UV-A GO:0070141 9.54 AKT1 CCND1 EGFR
30 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.52 MLH1 MSH2
31 positive regulation of protein phosphorylation GO:0001934 9.17 ADAM17 AKT1 CCND1 EGFR HRAS KRAS
32 positive regulation of transcription by RNA polymerase II GO:0045944 10.11 AKT1 CTNNB1 EGFR HRAS TLR9 TP53
33 cellular response to DNA damage stimulus GO:0006974 10.02 AKT1 CCND1 MLH1 MSH2 TP53

Molecular functions related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.91 AKT1 CDH1 KIT MSH2 TLR9 VEGFA
2 nucleotide binding GO:0000166 9.72 AKT1 EGFR HRAS KIT KRAS
3 protein phosphatase binding GO:0019903 9.54 CTNNB1 EGFR TP53
4 mismatched DNA binding GO:0030983 9.46 MLH1 MSH2
5 protein kinase binding GO:0019901 9.43 AKT1 CCND1 CTNNB1 EGFR MSH2 TP53
6 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.4 EGFR KIT
7 nitric-oxide synthase regulator activity GO:0030235 9.26 AKT1 EGFR
8 enzyme binding GO:0019899 9.17 AKT1 CCND1 CTNNB1 EGFR MSH2 TP53
9 guanine/thymine mispair binding GO:0032137 9.16 MLH1 MSH2

Sources for Gastrointestinal System Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....